CL2017001377A1 - Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos - Google Patents
Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismosInfo
- Publication number
- CL2017001377A1 CL2017001377A1 CL2017001377A CL2017001377A CL2017001377A1 CL 2017001377 A1 CL2017001377 A1 CL 2017001377A1 CL 2017001377 A CL2017001377 A CL 2017001377A CL 2017001377 A CL2017001377 A CL 2017001377A CL 2017001377 A1 CL2017001377 A1 CL 2017001377A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation
- crystal form
- crystalline form
- term
- new crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A UNA NUEVA FORMA CRISTALINA DE UN DERIVADO DE BENCIMIDAZOL Y UN PROCEDIMIENTO DE PREPARACIÓN DE ESTOS. LA NUEVA FORMA CRISTALINA DE ACUERDO CON LA PRESENTE INVENCIÓN APENAS CAMBIA DE FORMA QUÍMICA Y/O FÍSICA EN UN ESTADO DE FOTO-ESTRÉS DE LARGO PLAZO, TIENE HIGROSCOPICIDAD BAJA Y TIENE UNA CAPACIDAD INDUCTORA DE ELECTRICIDAD ESTÁTICA EXTREMADAMENTE BAJA, DE ESTE MODO ES VENTAJOSA PARA LA FORMULACIÓN, Y DEBIDO A LA EXCELENTE ESTABILIDAD DE LA FORMA DE CRISTAL MISMA, ES MUY ÚTIL PARA EL ALMACENAMIENTO A LARGO PLAZO DEL COMPUESTO.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150009326A KR101684053B1 (ko) | 2015-01-20 | 2015-01-20 | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001377A1 true CL2017001377A1 (es) | 2017-12-15 |
Family
ID=56417901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001377A CL2017001377A1 (es) | 2015-01-20 | 2017-05-30 | Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9908870B2 (es) |
| EP (1) | EP3248967B1 (es) |
| JP (2) | JP6535748B2 (es) |
| KR (1) | KR101684053B1 (es) |
| CN (2) | CN107207478B (es) |
| AR (1) | AR103444A1 (es) |
| BR (1) | BR102016001167B1 (es) |
| CL (1) | CL2017001377A1 (es) |
| CO (1) | CO2017005396A2 (es) |
| CY (1) | CY1123423T1 (es) |
| DK (1) | DK3248967T3 (es) |
| EA (1) | EA030919B1 (es) |
| EC (1) | ECSP17035416A (es) |
| ES (1) | ES2816646T3 (es) |
| GE (1) | GEP20196974B (es) |
| HR (1) | HRP20201275T1 (es) |
| HU (1) | HUE050979T2 (es) |
| IL (1) | IL253186B (es) |
| JO (1) | JO3592B1 (es) |
| LT (1) | LT3248967T (es) |
| MX (1) | MX359916B (es) |
| MY (1) | MY186830A (es) |
| PH (2) | PH12016000029B1 (es) |
| PL (1) | PL3248967T3 (es) |
| PT (1) | PT3248967T (es) |
| RS (1) | RS60758B1 (es) |
| SA (1) | SA517381904B1 (es) |
| SG (1) | SG10201509488YA (es) |
| SI (1) | SI3248967T1 (es) |
| TW (1) | TWI589575B (es) |
| UY (1) | UY36521A (es) |
| WO (1) | WO2016117814A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101829706B1 (ko) | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 산부가염 |
| KR20230114164A (ko) | 2022-01-24 | 2023-08-01 | 엠에프씨 주식회사 | 벤즈이미다졸 유도체의 공동 무정형 고형체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| KR20230114163A (ko) | 2022-01-24 | 2023-08-01 | 엠에프씨 주식회사 | 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법 |
| KR20240028127A (ko) | 2022-08-24 | 2024-03-05 | 위더스제약주식회사 | 테고프라잔 고체분산체 조성물 |
| WO2024045255A1 (zh) * | 2022-08-30 | 2024-03-07 | 上海皓元医药股份有限公司 | 一种特戈拉赞晶型b及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR043063A1 (es) | 2002-12-13 | 2005-07-13 | Altana Pharma Ag | Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas |
| US7256294B2 (en) * | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
| ATE442140T1 (de) * | 2005-06-14 | 2009-09-15 | Raqualia Pharma Inc | Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten |
| EP1963311B1 (en) * | 2005-12-19 | 2010-06-16 | RaQualia Pharma Inc | Chromane substituted benzimidazoles and their use as acid pump inhibitors |
| EP2318411A2 (en) * | 2008-07-03 | 2011-05-11 | Ratiopharm GmbH | Crystalline salts of sitagliptin |
| KR101605063B1 (ko) * | 2009-07-09 | 2016-03-21 | 라퀄리아 파마 인코포레이티드 | 소화관 운동이상이 관여하는 질환의 치료용 산 펌프 길항제 |
| JP2014047304A (ja) * | 2012-08-31 | 2014-03-17 | Sanyo Chem Ind Ltd | 樹脂粒子の製造方法 |
| GB2508352B (en) * | 2012-11-28 | 2017-08-16 | Douwe Egberts Bv | Treating soluble coffee |
| WO2014110344A1 (en) * | 2013-01-11 | 2014-07-17 | Novartis Ag | Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors |
| EA033632B1 (ru) * | 2014-12-19 | 2019-11-12 | Glaxosmithkline Ip Dev Ltd | 3-(6-АЛКОКСИ-5-ХЛОРБЕНЗО[d]ИЗОКСАЗОЛ-3-ИЛ)ПРОПИОНОВАЯ КИСЛОТА, ПОЛЕЗНАЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНУРЕНИНМОНООКСИГЕНАЗЫ |
-
2015
- 2015-01-20 KR KR1020150009326A patent/KR101684053B1/ko active IP Right Grant
- 2015-11-18 DK DK15879068.3T patent/DK3248967T3/da active
- 2015-11-18 GE GEAP201514554A patent/GEP20196974B/en unknown
- 2015-11-18 PL PL15879068T patent/PL3248967T3/pl unknown
- 2015-11-18 EP EP15879068.3A patent/EP3248967B1/en active Active
- 2015-11-18 HU HUE15879068A patent/HUE050979T2/hu unknown
- 2015-11-18 ES ES15879068T patent/ES2816646T3/es active Active
- 2015-11-18 JP JP2017537963A patent/JP6535748B2/ja active Active
- 2015-11-18 PT PT158790683T patent/PT3248967T/pt unknown
- 2015-11-18 SI SI201531354T patent/SI3248967T1/sl unknown
- 2015-11-18 SG SG10201509488YA patent/SG10201509488YA/en unknown
- 2015-11-18 WO PCT/KR2015/012385 patent/WO2016117814A2/ko active Application Filing
- 2015-11-18 LT LTEP15879068.3T patent/LT3248967T/lt unknown
- 2015-11-18 US US15/543,941 patent/US9908870B2/en active Active
- 2015-11-18 CN CN201580073998.0A patent/CN107207478B/zh active Active
- 2015-11-18 EA EA201791151A patent/EA030919B1/ru unknown
- 2015-11-18 RS RS20201062A patent/RS60758B1/sr unknown
- 2015-11-18 CN CN202010070896.6A patent/CN111187259B/zh active Active
-
2016
- 2016-01-19 UY UY0001036521A patent/UY36521A/es unknown
- 2016-01-19 MX MX2016000751A patent/MX359916B/es active IP Right Grant
- 2016-01-19 JO JOP/2016/0008A patent/JO3592B1/ar active
- 2016-01-19 AR ARP160100123A patent/AR103444A1/es unknown
- 2016-01-19 TW TW105101516A patent/TWI589575B/zh active
- 2016-01-19 PH PH12016000029A patent/PH12016000029B1/en unknown
- 2016-01-19 BR BR102016001167-1A patent/BR102016001167B1/pt active IP Right Grant
- 2016-01-20 MY MYPI2016000101A patent/MY186830A/en unknown
-
2017
- 2017-05-30 CO CONC2017/0005396A patent/CO2017005396A2/es unknown
- 2017-05-30 CL CL2017001377A patent/CL2017001377A1/es unknown
- 2017-06-07 EC ECIEPI201735416A patent/ECSP17035416A/es unknown
- 2017-06-26 IL IL253186A patent/IL253186B/en active IP Right Grant
- 2017-07-12 SA SA517381904A patent/SA517381904B1/ar unknown
-
2019
- 2019-04-03 JP JP2019071121A patent/JP2019104760A/ja not_active Withdrawn
- 2019-12-05 PH PH12019000462A patent/PH12019000462A1/en unknown
-
2020
- 2020-08-13 HR HRP20201275TT patent/HRP20201275T1/hr unknown
- 2020-08-27 CY CY20201100808T patent/CY1123423T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001377A1 (es) | Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| DOP2017000267A (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| AR106192A1 (es) | Formas cristalinas de un agente antiviral contra la hepatitis b | |
| CL2017001617A1 (es) | Formas sólidas de un inhibidor ask1 referencia cruzada a aplicaciones relacionadas | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| AR122183A2 (es) | Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato | |
| CR20180069A (es) | Derivados de la sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| CO2017003279A2 (es) | Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2 | |
| CL2017000792A1 (es) | Derivados del ácido borónico | |
| AR096344A1 (es) | Compuestos de elastómeros, mezclas y métodos para preparar los mismos | |
| EA201792021A1 (ru) | Ингибитор jak | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| AR103350A1 (es) | Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| CR20160224A (es) | Composición herbicida que comprende inhibidores ACC | |
| CL2019002321A1 (es) | Procesos para preparar ag-10, sus intermediarios, y sales de los mismos. | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| BR112016015190A2 (pt) | Composição farmacêutica não contendo antioxidante e método de preparação da mesma | |
| CL2017001521A1 (es) | Supresión de iarn parental de genes de remodelación de cromatina para controlar plagas hemipteranas | |
| AR098592A1 (es) | Formas cristalinas de 1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azulenos | |
| DOP2015000299A (es) | Derivados de prodroga de triazolpiridinas sustituidas |